Concord Biotech Limited has informed the Exchange about Copy of Newspaper Publication
CONCORDBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Concord Biotech has submitted copies of newspaper clippings of its unaudited standalone and consolidated Q1 FY26 financial results, published on August 9, 2025 in Financial Express (English, all editions) and Financial Express (Gujarati, Ahmedabad edition). This is a routine SEBI compliance filing under Regulation 47 of the LODR Regulations, 2015. As reported in the published results, consolidated revenue from operations stood at Rs 20,398.76 lakhs, down from Rs 21,580.17 lakhs in Q1 FY25, while consolidated net profit (after tax) declined to Rs 4,123.90 lakhs from Rs 5,976.24 lakhs a year ago. Consolidated basic EPS came in at Rs 3.94 versus Rs 5.70 in the year-ago quarter. The results were approved by the Board on August 8, 2025.
The filing itself is a procedural compliance disclosure and unlikely to move the stock. However, the underlying Q1 numbers show a notable year-on-year decline in both revenue (~5.5%) and net profit (~31%), which investors should weigh when assessing the stock's near-term earnings trajectory.